Pore by Pore

Start with what you are seeing.

Part of the CoreAge Rx promotional publishing network. Read the disclosure.

← Back to the library

Comparison · Public documents checked September 27, 2026

Clogged-pore products by format: a disclosed commercial shortlist

Compare a cream, a water-based solution and a cleanser without assuming that visible pores establish an acne diagnosis.

Editorial source review, with no clinician sign-off or firsthand treatment experience claimed.

A product roundup can hide a basic mismatch: one item is described as a cream, another as a serum, and another as a wash. All may appear in a clogged-pores search. This shortlist makes their documented formats visible and asks what each record actually supports. It does not choose treatment from a skin description, rank clinical outcomes or assemble the products into a routine.

CoreAge Rx appears first because Pore by Pore belongs to its promotional publishing network. The order is a commercial publishing choice, not an independent finding that Pore Favor works best. Our September 27, 2026 review covers current public manufacturer and provider records. No product testing, patient consultation, purchase or comparative clinical trial was performed for this article.

In this article

Use concern language as a starting point

The AAD's discussion of noticeable pores includes multiple contributing contexts, including oiliness, acne, irritation and loss of firmness. That makes a search phrase an incomplete comparison criterion. A product marketed for acne and a product promising smoother-looking texture may be addressing overlapping but different goals. AAD guidance.

Before interpreting any position in a list, distinguish the advertised concern from an assessed condition. Our guide to visible pores and blackheads explains that boundary. There is no requirement that every visible opening should disappear, and this shortlist offers no image-based assessment or promise to erase pores.

First commercial feature: CoreAge Pore Favor cream

The CoreAge FAQ identifies a cream, while its landing page advertises salicylic acid 2%, niacinamide 8%, zinc oxide 5% and urea 2%. It describes provider review and pharmacy preparation when appropriate. The complete base and supplied quantity are not established by those advertised percentages. PDP and offer.

CoreAge identifies compounding; FDA does not approve compounded drugs or verify their safety, effectiveness and quality before marketing. That limitation must remain visible beside the commercial placement. The Pore Favor review examines its care-access and pricing questions without treating prescription status as proof of superior performance. FDA explanation.

CeraVe: an acne cleanser that is rinsed off

CeraVe Acne Control Cleanser is the specific gel-to-foam product reviewed here. The current manufacturer page identifies salicylic acid 2%, acne-prone oily skin and claims concerning acne, blackheads and pore appearance. Its L’Oreal Drug Facts record calls the purpose acne treatment and includes rinsing in the directions. This is not CeraVe's similarly named Renewing SA Cleanser. Manufacturer page and exact label.

The ingredient list on the website differs from that posted labeling record. That unresolved version detail is discussed in the CeraVe review. Rinse-off format identifies a product category; it does not prove that the product will be gentler or less effective than a leave-on preparation.

The Ordinary: a water-based leave-on solution

The US Salicylic Acid 2% Solution page identifies a water-based serum for acne-prone skin. Its active-ingredient panel identifies salicylic acid as the acne treatment. This article refers to that precise solution, not the brand's Anhydrous Solution or a wash-off masque. The names are close enough that retaining the full product title matters. US record.

Its Usage Details and FAQ do not state the same application-frequency wording. We do not select between them or combine them into advice. The Ordinary review treats that as a clarification question. A shared ingredient percentage does not make this serum equivalent to the compounded cream or the cleanser.

Compare charge units without inventing value

CoreAge's posted totals are $504 for 12 months, $300 for six, $168 for three and $70 for one. The corresponding displays are $42, $49.99, $55.99 and $69.99 per month. The Ordinary's current US 30 mL variant shows $6.03 against a $6.70 reference price. CeraVe displays $17.99 without an unambiguous size assignment in the captured page. CoreAge pricing, Ordinary offer, CeraVe price.

These are different units of sale. A bottle price supplies no verified duration, and a plan price supplies no confirmed container quantity here. We therefore do not calculate a cheapest effective month or cost per improvement.

A comfort claim does not cancel a warning

The cleanser and solution records include warnings that irritation and dryness are more likely with another topical acne medicine. Their additional ingredients and reassuring marketing descriptions do not remove those warnings. The compound likewise needs its own professional instructions rather than assumptions imported from either retail product. CeraVe warning and Ordinary warning.

FDA's Drug Facts explanation separates uses, warnings, directions and inactive ingredients because those fields answer different questions. A pore-related benefit phrase should not replace the rest of that record. Our claim-reading guide keeps the distinction practical. FDA label guide.

What would change the comparison

A clearer product record would establish the actual package, complete ingredient version, charge and intended assessment goal. Better clinical evidence would describe the people studied, the exact preparation and measured outcomes. Those are different improvements; a more detailed retail page alone would not become a head-to-head trial.

For personal concerns that persist or involve more than an appearance preference, assessment matters more than the order of a sponsored list. The progress-record guide helps distinguish a change in shine, visible bumps or comfort without claiming what caused it. No clinical winner can be inferred from the three formats or their prices.

Sources behind this reading

  1. American Academy of Dermatology: making pores less noticeable ↗Medical society patient guidance · Checked 2026-09-27
  2. CoreAge Rx Pore Favor product description ↗Provider product page · Checked 2026-09-27
  3. CoreAge Rx Pore Favor current offer ↗Provider offer page · Checked 2026-09-27
  4. FDA: compounding questions and answers ↗Regulator explanation · Checked 2026-09-27
  5. CeraVe Acne Control Cleanser: exact US product ↗Manufacturer product page · Checked 2026-09-27
  6. CeraVe Acne Control Cleanser: L’Oreal Drug Facts record ↗Official labeling record; revised March 2025 · Checked 2026-09-27
  7. The Ordinary Salicylic Acid 2% Solution: current US product ↗Manufacturer product and acne-treatment labeling · Checked 2026-09-27
  8. FDA: reading an OTC Drug Facts label ↗Regulator consumer labeling guidance · Checked 2026-09-27
See the complete source register →